Talis Biomedical Corporation
TLIS · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.09 | 0.02 | -0.04 |
| FCF Yield | -73.75% | -41.50% | -83.07% | -106.84% |
| EV / EBITDA | 2.71 | 2.57 | 3.04 | 3.51 |
| Quality | ||||
| ROIC | -13.61% | -11.60% | -15.21% | -16.70% |
| Gross Margin | 0.00% | -267.12% | -311.92% | 92.11% |
| Cash Conversion Ratio | 1.28 | 0.49 | 0.84 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -52.59% | -46.81% | 744,001.89% | 220.71% |
| Free Cash Flow Growth | -76.29% | 42.94% | -0.45% | 24.02% |
| Safety | ||||
| Net Debt / EBITDA | 4.33 | 3.69 | 3.99 | 4.15 |
| Interest Coverage | 0.00 | 0.00 | -12.44 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,060.71 | -1,207.94 | -163.94 | -40,449.08 |